Skip to main content

23andMe Raises Additional $9M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Direct-to-consumer genomics firm 23andMe today announced it has raised an additional $9 million in its Series C financing round, bringing the total funding in the round to $31 million.

MPM Capital joined Johnson & Johnson Development Corp. as a new investor, the Mountain View, Calif.-based firm said. Ashley Ledbetter Dombkowski, a director at MPM, is joining 23andMe's board, it added.

In November, the company said it had raised $22 million in the round. The funding will be used to accelerate the firm's research, it added.

Along with MPM and J&J, other investors in 23andMe include Roche Venture Fund, Google Ventures, and New Enterprise Associates.

In a statement, 23andMe CEO Anne Wojcicki said the firm "has aligned a powerful constellation of expertise in strategic healthcare, healthcare venture funding, consumer markets, information technology, and business strategy that will enable us to bring the vision of personalized medicine to consumers faster."

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.